Vorolanib
As of the edition of 20 October 2026, Vorolanib is a small molecule: in active development; acts on FLT1, FLT4 and KDR and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 19, 2 stopped early
- Disease areas
- Cancer; Eye; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 2 | 1 |
| Phase 2 | 10 | 4 | 4 | 1 |
| Phase 3 | 5 | 0 | 5 | 0 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| EyePoint Pharmaceuticals | Lead sponsor of trials | 2021 to now |
| Betta Pharmaceuticals | Lead sponsor of trials | 2026 to now |